Cipher Pharmaceuticals Inc
F:PHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cipher Pharmaceuticals Inc
F:PHE
|
CA |
|
China Mobile Ltd
F:CTM
|
CN |
|
Siemens AG
F:SIE
|
DE |
|
Societatea de Producere a Energiei Electrice in Hidrocentrale Hidroelectrica SA
F:E28
|
RO |
|
H
|
HAL Trust
OTC:HALFF
|
NL |
|
C
|
Cipher Pharmaceuticals Inc
SWB:PHE
|
CA |
Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals is a specialty drug company that focuses on dermatology and a small number of other prescription products. It does not run a large research lab or a broad drug factory network. Instead, it buys or licenses medicines that already exist or are close to market, then develops, registers, and sells them in the markets where it thinks they can win a place. The company makes money mainly by selling prescription medicines through pharmacies and healthcare channels, and in some cases by earning royalties or other rights-based income from licensed products. Its main customers are doctors who prescribe the drugs, pharmacies that dispense them, and patients who use them, with hospitals and healthcare distributors also playing a role depending on the product. Cipher’s products are aimed at specific treatment areas, so its business depends more on focused brand building, regulatory approvals, and sales execution than on mass-market consumer demand. What makes Cipher different is its role as a small, focused commercializer of niche pharmaceutical products. It looks for medicines that can be taken through approval and brought to market without the cost and risk of discovering drugs from scratch. That model can be attractive in specialty medicine because a single approved product can serve a clear medical need and build a durable business if it is well supported by physicians and pharmacists.
Cipher Pharmaceuticals is a specialty drug company that focuses on dermatology and a small number of other prescription products. It does not run a large research lab or a broad drug factory network. Instead, it buys or licenses medicines that already exist or are close to market, then develops, registers, and sells them in the markets where it thinks they can win a place.
The company makes money mainly by selling prescription medicines through pharmacies and healthcare channels, and in some cases by earning royalties or other rights-based income from licensed products. Its main customers are doctors who prescribe the drugs, pharmacies that dispense them, and patients who use them, with hospitals and healthcare distributors also playing a role depending on the product. Cipher’s products are aimed at specific treatment areas, so its business depends more on focused brand building, regulatory approvals, and sales execution than on mass-market consumer demand.
What makes Cipher different is its role as a small, focused commercializer of niche pharmaceutical products. It looks for medicines that can be taken through approval and brought to market without the cost and risk of discovering drugs from scratch. That model can be attractive in specialty medicine because a single approved product can serve a clear medical need and build a durable business if it is well supported by physicians and pharmacists.
Revenue: Cipher reported second-quarter net revenue of $12.1 million, down 10% from a year ago, as weaker Natroba sales and lower licensing revenue outweighed growth at Epuris.
Natroba: U.S. Natroba sales were pressured by Medicaid-related market dynamics, but management said its expectations for the product have not changed and it is leaning into commercial channels, direct-to-patient, retail stocking, and same-day delivery.
Epuris: Epuris grew 14% year over year to $4.1 million, with 8% higher sales volumes and market share up to 47.1% as of June 30.
Reimbursement: Cipher signed a letter of intent with the pCPA that is expected to expand public reimbursement coverage for Epuris across Canada, which management believes should widen patient access and support future growth.
Profitability: Adjusted EBITDA fell to $6.8 million in the quarter, but margins remained high, with management highlighting 57% quarterly margin and 59% year-to-date margin.
Business development: Management remains active on acquisitions, in-licensing, and out-licensing, but walked away from one advanced acquisition process because product concerns and price made it unattractive.